Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT - PubMed (original) (raw)

Clinical Trial

Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT

Mohan Doss et al. Nucl Med Commun. 2010 Dec.

Abstract

Objectives: F-HX4 is a novel positron emission tomography (PET) tracer for imaging hypoxia. The purpose of this study was to determine the biodistribution and estimate the radiation dose of F-HX4 using whole-body PET/computed tomography (CT) scans in monkeys and humans.

Methods: Successive whole-body PET/CT scans were done after the injection of F-HX4 in four healthy humans (422±142 MBq) and in three rhesus monkeys (189±3 MBq). Biodistribution was determined from PET images and organ doses were estimated using OLINDA/EXM software.

Results: The bladder, liver, and kidneys showed the highest percentage of the injected radioactivity for humans and monkeys. For humans, approximately 45% of the activity is eliminated by bladder voiding in 3.6 h, and for monkeys 60% is in the bladder content after 3 h. The critical organ is the urinary bladder wall with the highest absorbed radiation dose of 415±18 (monkeys) and 299±38 μGy/MBq (humans), in the 4.8-h bladder voiding interval model. The average value of effective dose for the adult male was estimated at 42±4.2 μSv/MBq from monkey data and 27±2 μSv/MBq from human data.

Conclusion: Bladder, kidneys, and liver have the highest uptake of injected F-HX4 activity for both monkeys and humans. The urinary bladder wall receives the highest dose of F-HX4 and is the critical organ. Thus, patients should be encouraged to maintain adequate hydration and void frequently. The effective dose of F-HX4 is comparable with that of other F-based imaging agents.

Trial registration: ClinicalTrials.gov NCT00606424.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Synthesis of 18F-HX4 from Precursor

Fig. 2

Fig. 2

Decay-corrected anterior maximum-intensity projections of PET at 17, 82, 120, 156, and 199 min (from left to right) after injection of 18F-HX4 in a female volunteer. There is rapid clearance of activity in kidneys, liver and bladder. Gallbladder activity peaks at 82 min then decreases with time

Fig. 3

Fig. 3

Mean percentage of injected activity and standard deviation (SD) for top 3 organs determined on the basis of 4 18F-HX4 PET emission scans in human volunteers, as a function of time after injection. Rapid clearance of activity is observed in the organs

Fig. 4

Fig. 4

Decay-corrected anterior maximum-intensity projections of PET at 3, 13, 40, 77 and 187 min (from left to right) after injection of 18F-HX4 in a rhesus monkey. The liver and kidney activities decrease rapidly with time, and bladder accumulates activity with time (there is no voiding of bladder as the monkey is anesthetized)

Fig. 5

Fig. 5

Mean percentage of injected activity and standard deviation (SD) for top three organs determined on the basis of three rhesus monkey 18F-HX4 PET emission scans, as a function of time after injection. Liver and kidney activities decrease rapidly with time, and bladder activity increases with time (there is no voiding as monkeys are anesthetized)

Similar articles

Cited by

References

    1. Lucignani G. PET imaging with hypoxia tracers: a must in radiation therapy. Eur J Nucl Med Mol Imaging. 2008;35:838–42. - PubMed
    1. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699–757. - PubMed
    1. Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist. 2008;13 3:21–6. - PubMed
    1. Zeng L, Ou G, Itasaka S, Harada H, Xie X, Shibuya K, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci. 2008;99:2327–35. - PMC - PubMed
    1. Zaffaroni N, Fiorentini G, De Giorgi U. Hyperthermia and hypoxia: new developments in anticancer chemotherapy. Eur J Surg Oncol. 2001;27:340–2. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources